The transaction builds on the successful partnership between Fresenius and mAbxience established in 2022.

此次交易建立在费森尤斯与mAbxience于2022年建立的 successful 合作伙伴关系基础之上。

Full ownership creates a stronger platform to enhance quality and supply resilience, while supporting future innovation and broader patient access to high-quality biosimilars.

全资拥有将打造一个更强大的平台，以提升质量和供应韧性，同时支持未来创新并扩大患者对高质量生物类似药的可及性。

mAbxience will continue supporting its existing customers and remains fully committed to maintaining quality and reliable supply of its biosimilars.

mAbxience 将继续为其现有客户提供支持，并始终致力于确保其生物类似药的质量和可靠供应。

MADRID

马德里

,

，

Oct. 1, 2026

2026年10月1日

/PRNewswire/ -- mAbxience today announced that Fresenius SE & Co. KGaA has acquired the remaining 45% of mAbxience from Insud Pharma, building on the successful partnership established between the two companies in 2022 and marking the beginning of a new phase of growth for the company.

/美通社/ -- mAbxience 今日宣布，费森尤斯集团（Fresenius SE & Co. KGaA）已从Insud Pharma收购mAbxience剩余的45%股份。此举建立在双方于2022年建立的成功合作伙伴关系基础之上，标志着公司进入一个新的增长阶段。

Continue Reading

继续阅读

Fresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansion

费森尤斯完成对mAbxience的收购，为未来产品组合扩张打造更强大的平台

Fresenius acquired a 55% majority stake in mAbxience in August 2022 and has consolidated the business since then. Full ownership completes that structure: mAbxience biosimilars platform is now wholly owned within Fresenius Kabi's Biopharma business, which covers the full value chain from development and manufacturing through to commercialization..

费森尤斯于2022年8月收购了mAbxience的55%多数股权，并自那时起将其业务纳入合并报表。实现全资控股后，这一架构得以完善：mAbxience的生物类似药平台现在由费森尤斯卡比旗下的生物制药业务完全拥有，该业务涵盖了从研发和生产到商业化的完整价值链。

The acquisition builds on a successful partnership that has already delivered important development, manufacturing, technology-transfer and regulatory milestones. This collaboration has contributed to the expansion of manufacturing capabilities, the advancement of technology transfer programs and the strengthening of mAbxience's position as a global biopharmaceutical company.

此次收购建立在一段成功的合作伙伴关系之上，该合作已实现了重要的开发、制造、技术转让和监管里程碑。这一协作有助于扩大制造能力，推进技术转让项目，并巩固 mAbxience 作为全球生物制药公司的地位。

Bringing the organizations together under full ownership creates a stronger platform to enhance quality and supply resilience, while supporting future innovation and broader patient access to high-quality biosimilars at a time when a large wave of biologics is losing exclusivity..

通过全资整合这些组织，我们打造了一个更强大的平台，以提升质量与供应链韧性，同时支持未来创新，并在大批生物制剂专利独占期届满之际，扩大患者对高质量生物类似药的可及性。

Michael Sen, Chief Executive Officer of Fresenius

费森尤斯首席执行官迈克尔·森

, said:

，说：

'

'

Completing the acquisition of mAbxience marks the next milestone in building a leading, vertically integrated biopharma business at scale. When we first invested in mAbxience four years ago, the market opportunity was promising but still evolving. Our initial majority stake gave us access to a highly competitive platform while managing risk.

完成对mAbxience的收购标志着我们在打造一家具有规模优势的领先垂直整合生物制药企业进程中迈出了下一个里程碑。四年前，我们首次投资mAbxience时，市场机遇虽前景广阔但仍处于演变阶段。我们最初获得的多数股权使我们能够在控制风险的同时，接入一个极具竞争力的平台。

Since then, the market has developed strongly, mAbxience has delivered, and Fresenius now has the financial strength to take this next step. Full ownership gives us complete control over cost, capacity and launch timing, and full economic benefit, as the next wave of biologics loses exclusivity. For patients, that means dependable access to high-quality biosimilars; for shareholders, it is a disciplined investment in a business we know well..

自那时以来，市场强劲发展，mAbxience 已实现交付目标，而费森尤斯如今具备雄厚的财务实力来迈出这下一步。随着下一波生物制剂失去专利独占权，全资拥有使我们能够完全掌控成本、产能和上市时机，并获得全部经济效益。对患者而言，这意味着能够可靠地获得高质量的生物类似药；对股东而言，这是对我们熟知的业务所进行的审慎投资。

'

'

Jurgen van Broeck, Chief Executive Officer of mAbxience

mAbxience 首席执行官 Jurgen van Broeck

, said: '

，说：‘

mAbxience was founded to serve patients, while proving that world-class biologics could be developed and manufactured at a cost the world could afford.  Since 2022, our partnership with Fresenius has demonstrated the strength of combining our people, expertise and capabilities. I would also like to recognize and thank Insud Pharma for its support and commitment over the past decade.

mAbxience 的成立旨在服务患者，同时证明世界一流的生物药能够以全球可负担的成本进行开发和生产。自2022年以来，我们与费森尤斯的合作彰显了我们团队、专业知识和能力相结合的强大力量。我还要感谢 Insud Pharma 在过去十年中给予的支持与承诺。

The success of mAbxience today is built on the vision, dedication and hard work of many people who have contributed to this journey from the very beginning. Full ownership is the natural next step and creates an even stronger platform for innovation, growth and long-term impact for patients, customers, and partners.

mAbxience 今日的成功，源于众多自始至终为这一历程做出贡献的人们的远见、奉献与辛勤工作。实现完全控股是顺理成章的下一步举措，将为患者、客户和合作伙伴打造一个更加强大的创新、增长及长期影响平台。

As we begin this next chapter together, we will continue to build on the entrepreneurial spirit, scientific expertise and commitment to patients that have driven mAbxience's success..

当我们共同开启这一新篇章时，我们将继续弘扬推动 mAbxience 取得成功的创业精神、科学专长以及对患者的承诺。

'

'

mAbxience will continue to support its existing customers and partners, and the company remains fully committed to maintaining quality, reliable supply and the delivery of its ongoing commitments worldwide.

mAbxience 将继续支持其现有客户和合作伙伴，公司仍 fully 致力于维持质量、可靠的供应以及在全球范围内履行其持续承诺。

Jurgen Van Broeck, Chief Executive Officer of mAbxience, will continue to lead the business, reporting to Dr. Sang-Jin Pak, President Biopharma at Fresenius.

mAbxience 首席执行官 Jurgen Van Broeck 将继续领导公司业务，并向费森尤斯生物制药总裁 Sang-Jin Pak 博士汇报。

SOURCE mAbxience

来源 mAbxience

21

二十一

%

百分之

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示